Shares of BioCryst Pop on Merger Termination, But Gains Temporary
- BioCryst Pharmaceuticals (BCRX) gapped up 80% to $2.88 on Friday’s open, only to retrace to more conservative gains – albeit considerable – of 25%, or … Continue Reading
Read nowAuthor Archives: Jake King
TEVA: Lower Expectations Out of the Way, Stock Should Climb into Investor Day
Long Ideas - In the wake of prior narrowed 2012 projections, Teva Pharmaceuticals (NYSE:TEVA) offered 2013 guidance on Friday morning that fell substantially short of Wall St. analyst … Continue Reading
Read nowAMRN Delays Hiring Decision; Stock Should Rally on Relief
- Amarin Corp. (AMRN) reported in an 8k Thursday morning that the company delayed a a decision on hiring a salesforce for its recently approved high-triglyceride … Continue Reading
Read nowSCLN On Solid Ground; Stock Cheap, And Large Investors Are Buying
Long Ideas - Some notable investors have significantly increased their positions in SciClone Pharmaceuticals (NASDAQ:SCLN) recently, and the stock is expected to work higher on this news plus … Continue Reading
Read nowAhead of Zecuity Decision, PATH Offers a Trading Opportunity
Long Ideas - On Tuesday morning, NuPathe Inc. (NASDAQ:PATH) announced the receipt of an $8.5M term loan, just a month after the company firmed up the balance sheet … Continue Reading
Read nowA Mixed Reaction to GILD’s Latest Data
Long Ideas - Gilead Sciences announced Tuesday morning that its Hepatitis C (HCV) candidate sofosbuvir (formerly GS-7977) in combination with ribavirin attained a 78% Sustained Virologic Response (SVR) … Continue Reading
Read nowMethylGene Poised to Move With New Management, Board, and Capital
Long Ideas - Despite closing a $26.1M private financing last Wednesday, shares of MethylGene (TSE:MYG) have yet to respond, but precedents suggest that MYG may be in for … Continue Reading
Read now